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The recognition over 25 years ago that the host response 
plays an exquisite role in systemic infections and sepsis led 
to the current standard sepsis definition. Unfortunately, 
the systemic inflammatory response syndrome (SIRS) cri-
teria turned out to be less useful than anticipated, lacking 
sensitivity, specificity, and ease of clinical application [1]. 
Had some of the novel host-response biomarkers been 
available then, it arguably would have been preferable to 
white blood cell (WBC) count as a laboratory-based SIRS 
criterion, considering the greater sensitivities and specifi-
cities for diagnosis of sepsis and provision of prognostic 
information demonstrated in a growing body of literature 
linking novel inflammatory markers to the presence and 
severity of sepsis [2]. Specific sepsis biomarkers have the 
ability to improve early sepsis recognition and severity 
assessment and may also help to guide therapeutic deci-
sions in individual patients, particularly when measured 
serially. Thereby, measurement of initial and follow-up 
biomarkers potentially allows transition from bundled 
sepsis care to more individualized, “personalized” sepsis 
management in single patients. In this issue of Clinical 
Chemistry and Laboratory Medicine (CCLM), several origi-
nal research papers provide novel insight into kinetics of 
inflammatory biomarker in different settings and patient 
population, thereby importantly advancing the field of 
biomarker research.
Among these emerging inflammatory sepsis markers, 
procalcitonin (PCT) is a promising candidate. PCT is upreg-
ulated by microbial toxins and certain pro-inflammatory 
mediators and is downregulated as these substances 
subside during recovery. PCT expression is attenuated by 
the cytokines typically released in response to a viral infec-
tion (e.g., interferon γ) [3]. PCT measurements may there-
fore be helpful in estimating the risk for sepsis, its course, 
and efficacy of sepsis treatments. Yet, there is an ongoing 
debate whether or not PCT provides more useful prog-
nostic information, also in regard to cost-effectiveness, 
compared with more traditional markers such as reactive 
protein as well as WBC count.
Herein, a secondary analysis from a prospective study 
with 925 community-acquired pneumonia patients pro-
vides interesting novel results by comparing the prog-
nostic potential of PCT, C-reactive protein (CRP), and 
WBC, both on admission and during follow-up in regard 
to mortality and treatment failure [4]. PCT, CRP, and to a 
lesser degree WBC provided prognostic information, par-
ticularly when considering their kinetics at days 5 and 7 
and when looking at adverse clinical outcomes instead 
of mortality alone. Importantly, kinetics of PCT and CRP 
also improved routinely recommended clinical risk scores 
– such as CURB65. Whether such combinations, however, 
will change management of patients and thereby poten-
tially reduce length of hospital stay could not be answered 
by this study.
Regarding the kinetics of inflammatory markers, a 
study authored by Dr. Hoffmann and colleagues describe 
in great depth the dynamics of four established markers 
(PCT, CRP, WBC, thrombocyte counts) and two novel 
potential markers (granularity index, δ-hemoglobin) 
during the onset and resolution of a high-grade inflamma-
tion over a time period of 168 h in more than 1000 patients 
[5]. The study illustrates the different trajectories of the 
markers and the importance of blood sample timing in 
regard to the interpretation of results.
Another interesting sepsis marker is presepsin, the 
fragment of soluble CD14, which consists of 64 amino acid 
residues and originates from the cleavage of the CD14 on 
the membrane surface by cathepsin and other lysosomal 
enzymes [6]. The study authored by Dr. Sargentini focused 
on a cohort of 21 critically ill, septic patients who showed 
a relapse of disease after initial resolution of illness. The 
authors found that both presepsin and PCT allowed differ-
entiation of healthy controls and septic patients with very 
high accuracy (area under the curve, 0.89 and 0.91); yet 
in patients with relapse of sepsis, PCT levels normalized 
during the transient remission period whereas presepsin 
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levels remained elevated. The study thus suggested that 
the combined use of these markers may allow early iden-
tification of relapse, which has important clinical con-
sequences in regard of early discharge and frequency of 
monitoring patients.
A similar conclusion was also drawn by a Korean study 
authored by Jekarl and colleagues where PCT, interleukin 
(IL) 6, and CRP had a high diagnostic yield for infection 
diagnosis [7]. Also, PCT, IL6, and IL5 had prognostic value 
and correlated with severity of sepsis. Finally, interferon 
(INF) γ had an inverse relationship with severity of sepsis. 
Again, this study emphasized the benefit of biomarker 
bundles for improved management of sepsis patients.
Although these markers may be influenced by trauma 
and surgical stress, the marker kinetics may still provide 
important clinical information. A study authored by 
Dr. Kyung Ran Jun and colleagues found that for the perio-
perative monitoring of patients, PCT showed good predic-
tive accuracy for adverse outcomes with less influence from 
surgical trauma compared to CRP and other markers [8].
Another emerging biomarker for sepsis diagno-
sis is expression of CD64 on neutrophils (CD64 index). 
Dr. Rogina and colleagues found an excellent discrimina-
tory value to predict sepsis as compared with other inflam-
matory markers in a cohort of 88 critically ill patients [9]. 
Although flow cytometer is needed for measurement of 
CD64 index, making it more expensive and laborious, the 
marker has high potential to improve sepsis diagnosis and 
management.
In regard to emerging technologies for PCT measure-
ments, a study from Italy [10] evaluated the analytical per-
formance of the novel diazyme PCT immunoturbidimetric 
assay on Beckman CoulterAU5800 as compared with the 
reference Kryptor technology. This novel technology has 
some technical and analytical advantages over Kryptor 
technology, including a lower volume of sample needed 
for measurements (i.e., 20 vs. 50 μL), a faster turnaround 
time (10 vs. 19 min), lower costs, as well as the high 
throughput. These benefits potentially make its availabil-
ity more widespread to different clinical laboratories. The 
study results were promising, showing high agreement 
between both methods, particularly when PCT concentra-
tions were  > 0.16 ng/mL.
Another study published in this issue of CCLM focused 
on potential cost savings associated with biomarker-
guided care, namely PCT-guided antibiotic stewardship 
[11]. The study used data from a recent large individual 
patient data meta-analysis including all 14 published anti-
biotic stewardship trials and a total of 4221 participants 
[12]. The study was adapted to the US setting by applying 
the meta-analytic results to US lengths of stay, costs, and 
practice patterns and found substantial savings associ-
ated with the use of PCT-guided care in across different 
respiratory infections and common US treatment settings. 
Extrapolated to the overall US population, the study esti-
mated total savings of $1.6 billion annually. Thereby, only 
direct costs associated with antibiotics and resource use 
was considered – and thus cost savings maybe even more 
extensive when considering also secondary effects such as 
reductions in antibiotic resistance and Clostridium  difficile 
infections.
Today’s available biomarker for sepsis diagnosis and 
prognostication are still far from being perfect. An overlap 
occurs in biomarker levels between SIRS patients with 
inflammation and no bacterial infection and patients with 
sepsis. This observation may partly relate to methodo-
logical difficulties in establishing a gold standard sepsis 
diagnosis in observational studies and to the heterogene-
ity of the types and severities of infections causing sepsis 
[11]. Yet, in addition to evaluating novel sepsis markers 
based on their ability to differentiate the sepsis syndrome 
using the arbitrary definition established many years 
ago, we should focus on the results of comparative effec-
tive research trials ultimately telling us whether or not a 
potential sepsis biomarker improves our ability to identify 
the at-risk population measured by clinical outcomes and 
antibiotic exposure. Among the different sepsis markers, 
PCT has been most thoroughly put on the spot, and results 
are encouraging [13]. Whether addition of other emerging 
markers can further improve these results should be inves-
tigated in future trials. The converging crises of increasing 
resistance and collapse of antibiotic research need urgent 
action. More widespread use of biomarker protocols is an 
evidence-based, first step to slow down the former trend 
while awaiting even more sophisticated biomarker algo-
rithms in the long run.
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